SILVERBACK ASSET MANAGEMENT LLC
Position in KPTI — Karyopharm Therapeutics Inc.
CIK 1278960
DURHAM, NC
Position in KPTI
as of Mar 31, 2026
· filed May 21, 2026
Position Value
$362,050
+$67,650 QoQ
Shares Held
65,000
+62.5% QoQ
Ownership
0.287%
of shares outstanding
% of Portfolio
1.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KPTI Over Time
Shares Held
Position Value (USD)
Derivatives in KPTI
reported options exposure · as of Mar 31, 2026CallValue
$557,000
CallShares
100,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026SILVERBACK ASSET MANAGEMENT LLC holds $1,006,550 across 2 Biotechnology names. KPTI ranks #2 (36.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EYPT |
EyePoint, Inc.
|
50,000 | $644,500 | |
| 2 | KPTI |
Karyopharm Therapeutics Inc.
This page
|
65,000 | $362,050 |
All Filings in KPTI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $557,000 | 100,000 | Call | Sole | 2026-05-21 | |
| 2026-03-31 | $362,050 | 65,000 | Shares | Sole | 2026-05-21 | |
| 2025-12-31 | $294,400 | 40,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $261,600 | 40,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $301,700 | 70,000 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $187,000 | 50,000 | Principal | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||